5-bromo-thiophene-2-sulfonic acid quinolin-8-ylamide | 620103-87-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 5-bromo-thiophene-2-sulfonic acid quinolin-8-ylamide
• 英文别名: 5-bromo-N-quinolin-8-ylthiophene-2-sulfonamide
• CAS: 620103-87-9
• 化学式: C₁₃H₉BrN₂O₂S₂
• mdl: MFCD06290688
• 分子量: 369.263
• InChiKey: BWZPDZRPJIBWAU-UHFFFAOYSA-N

物化性质

• 沸点：
  536.4±60.0 °C(Predicted)
• 密度：
  1.745±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  95.7
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 危险性防范说明：
  P264,P280,P302+P352,P305+P351+P338,P332+P313,P337+P313,P362
• 危险性描述：
  H315,H319

反应信息

• 作为产物：
  描述：

  8-氨基喹啉 、 5-溴噻吩-2-磺酰氯 在 吡啶 作用下， 反应 24.0h， 生成 5-bromo-thiophene-2-sulfonic acid quinolin-8-ylamide
  参考文献：
  名称：

  Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFκB activity within two separate high-throughput screens of NFκB activation

  摘要：

  We describe here a series of N-(quinolin-8-yl)benzenesulfonamides capable of suppressing the NF kappa B pathway identified from two high-throughput screens run at two centers of the NIH Molecular Libraries Initiative. These small molecules were confirmed in both primary and secondary assays of NF kappa B activation and expanded upon through analogue synthesis. The series exhibited potencies in the cell-based assays at as low as 0.6 mu M, and several indications suggest that the targeted activity lies within a common region of the NF kappa B pathway. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.10.100

文献信息

• Novel Sulfonaminoquinoline Hepcidin Antagonists
  申请人：Buhr Wilm

  公开号：US20120214803A1

  公开（公告）日：2012-08-23

  The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.

  本发明涉及新型肝铁蛋白拮抗剂，包括它们的药物组合物以及将其用作药物治疗铁代谢紊乱，特别是铁缺乏病和贫血等疾病，特别是与慢性炎症性疾病相关的贫血。
• PDE4B INHIBITORS AND USES THEREFOR
  申请人：Ibrahim Prabha N.

  公开号：US20090286793A1

  公开（公告）日：2009-11-19

  Compounds active on phosphodiesterase PDE4B are provided. Also provided herewith are compositions useful for treatment of PDE4B-mediated diseases or conditions, and methods for the use thereof.

  本发明提供了对磷酸二酯酶PDE4B活性作用的化合物。同时还提供了用于治疗PDE4B介导的疾病或病状的组合物以及其使用方法。
• US7585859B2
  申请人：——

  公开号：US7585859B2

  公开（公告）日：2009-09-08
• US8470821B2
  申请人：——

  公开号：US8470821B2

  公开（公告）日：2013-06-25
• US9102688B2
  申请人：——

  公开号：US9102688B2

  公开（公告）日：2015-08-11